GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients

Key Points • cGFAP and cNfL levels increase in pediatric patients during CAR T-cell–associated neurotoxicity, indicating injury to astrocytes and neurons.• Nervous system injury from prior therapy correlates with high baseline GFAP and NfL levels in pediatric patients eligible for CAR T cells.

[1]  M. Jensen,et al.  Modified manufacturing process modulates CD19CAR T-cell engraftment fitness and leukemia-free survival in pediatric and young adult subjects. , 2022, Cancer immunology research.

[2]  H. Shalabi,et al.  Immunotherapy Associated Neurotoxicity in Pediatric Oncology , 2022, Frontiers in Oncology.

[3]  M. Endres,et al.  Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy , 2022, JCI insight.

[4]  John K. Yue,et al.  Blood GFAP as an emerging biomarker in brain and spinal cord disorders , 2022, Nature Reviews Neurology.

[5]  M. von Bergwelt-Baildon,et al.  Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment , 2022, Blood advances.

[6]  A. Shih,et al.  Brain capillary obstruction during neurotoxicity in a mouse model of anti-CD19 chimeric antigen receptor T-cell therapy , 2021, Brain communications.

[7]  Amanda M Li,et al.  SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL , 2021, Blood.

[8]  T. Ziemssen,et al.  Serum neurofilament light chain in pediatric spinal muscular atrophy patients and healthy children , 2021, Annals of clinical and translational neurology.

[9]  C. Blag,et al.  Why Do Children with Acute Lymphoblastic Leukemia Fare Better Than Adults? , 2021, Cancers.

[10]  P. Svenningsson,et al.  A multicentre validation study of the diagnostic value of plasma neurofilament light , 2021, Nature Communications.

[11]  A. Winston,et al.  Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis , 2021, BMJ Neurology Open.

[12]  C. Turtle,et al.  Cytokines in CAR T Cell–Associated Neurotoxicity , 2020, Frontiers in Immunology.

[13]  S. Phipps,et al.  Neurocognitive functioning in long-term survivors of pediatric hematopoietic cell transplantation , 2020, Bone Marrow Transplantation.

[14]  É. Azoulay,et al.  Description of neurotoxicity in a series of patients treated with CAR T-cell therapy , 2020, Scientific Reports.

[15]  H. Weiner,et al.  Blood neurofilament light: a critical review of its application to neurologic disease , 2020, Annals of clinical and translational neurology.

[16]  Michael L. Wang,et al.  Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma. , 2020, Blood advances.

[17]  S. Nikiforow,et al.  Clinical Predictors of Neurotoxicity After Chimeric Antigen Receptor T-Cell Therapy. , 2020, JAMA neurology.

[18]  K. Blennow,et al.  Time course and diagnostic utility of NfL, tau, GFAP, and UCH-L1 in subacute and chronic TBI , 2020, Neurology.

[19]  Matthew J. Frigault,et al.  Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity , 2020, BMJ Neurology Open.

[20]  Amanda M Li,et al.  Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity. , 2020 .

[21]  Jae-Won Hyun,et al.  Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy , 2020, Scientific Reports.

[22]  P. Huppke,et al.  Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis , 2020, Neurology: Neuroimmunology & Neuroinflammation.

[23]  M. Perales,et al.  Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. , 2020, Blood advances.

[24]  Xiuhua Bozarth,et al.  EEG Correlates of Delirium in Children and Young Adults With CD19-Directed CAR T Cell Treatment-Related Neurotoxicity. , 2019, Journal of clinical neurophysiology : official publication of the American Electroencephalographic Society.

[25]  İ. Doğan.  Prognostic Value of Serum Neurofilaments in Patients with Clinically Isolated Syndromes , 2019, Turkish Journal Of Neurology.

[26]  R. Hevner,et al.  Glial injury in neurotoxicity after pediatric CD19‐directed chimeric antigen receptor T cell therapy , 2019, Annals of neurology.

[27]  Aaron J Johnson,et al.  GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. , 2019, Blood.

[28]  S. Grupp,et al.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. , 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  C. Turtle,et al.  Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies , 2018, CNS Drugs.

[30]  Ludwig Kappos,et al.  Neurofilaments as biomarkers in neurological disorders , 2018, Nature Reviews Neurology.

[31]  S. Nikiforow,et al.  Neuropathology of a Case With Fatal CAR T-Cell-Associated Cerebral Edema , 2018, Journal of neuropathology and experimental neurology.

[32]  L. Deangelis,et al.  Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. , 2018, Cancer discovery.

[33]  S. Kesler,et al.  Neurocognitive Outcomes and Interventions in Long-Term Survivors of Childhood Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  H. D. Liggitt,et al.  Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. , 2018, Cancer discovery.

[35]  A. Bleyer,et al.  Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia: A Review , 2018, JAMA oncology.

[36]  M. Wurfel,et al.  Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. , 2017, Cancer discovery.

[37]  S. Riddell,et al.  Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults. , 2017, Blood.

[38]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[39]  Y. T. Cheung,et al.  Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis. , 2016, The Lancet. Haematology.

[40]  F. Eichler,et al.  CSF and Blood Levels of GFAP in Alexander Disease , 2015, eNeuro.

[41]  D. Fuchs,et al.  Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients , 2014, PloS one.

[42]  E. Hansson,et al.  Astrocyte–endothelial interactions at the blood–brain barrier , 2006, Nature Reviews Neuroscience.